TY  - CHAP
M1  - Book, Section
TI  - Drug-Induced Hematologic Disorders
A1  - Greene, Elisa M.
A1  - Hagemann, Tracy M.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - KEY  CONCEPTS  The  most  common  drug-induced  hematologic  disorders  include  aplastic  anemia,  agranulocytosis,  megaloblastic  anemia,  hemolytic  anemia,  and  thrombocytopenia.  Drug-induced  hematologic  disorders  are  generally  rare  adverse  effects  associated  with  drug  therapy.  The  incidence  of  rare  adverse  drug  reactions  (ADRs)  is  usually  established  by  postmarketing  surveillance  and  reporting.  Rechallenging  a  patient  with  an  agent  suspected  of  inducing  a  blood  disorder  is  not  generally  recommended.  Drug-induced  hematologic  disorders  can  occur  by  two  mechanisms:  direct  drug  or  metabolite  toxicity  or  an  immune  reaction.  The  primary  treatment  of  drug-induced  hematologic  disorders  is  removal  of  the  drug  in  question  and  symptomatic  support  of  the  patient.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1145221578
ER  -